TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ProMIS Neurosciences ( (PMN) ) just unveiled an announcement.
On November 17, 2025, ProMIS Neurosciences Inc. held a special meeting of shareholders to vote on two key proposals. The first proposal, which was approved, involved authorizing a potential share consolidation at a ratio determined by the Board within a year. The second proposal, also approved, allowed for the adjournment of the meeting if necessary to solicit additional proxies. These decisions could impact the company’s stock structure and shareholder engagement strategies.
The most recent analyst rating on (PMN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences Inc. operates in the biotechnology industry, focusing on developing therapeutic solutions for neurodegenerative diseases.
Average Trading Volume: 1,417,108
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.42M
Learn more about PMN stock on TipRanks’ Stock Analysis page.